# US 2010/0167286 A1 · Pluripotent cell lines and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167286 A1
- Document ID: US20100167286A1
- Status: Published application
- Kind: A1
- Application number: 12/459,019
- Filed: 2009-06-24
- Published: 2010-07-01
- Earliest claimed: 2008-06-24
- Assignees: Parkinson's Institute; The Board of Trustees of the Leland Stanford Junior University
- Inventors: Renee Ann Reijo Pera; J. William Langston; Birgitt Schüle; Theodore D. Palmer; Blake Byers; Ha Nam Nguyen; James Anthony Byrne; Brandon John Cord
- Web page: https://patentgrep.com/patent/US20100167286A1

## CPC

- C12N 5/0619: {Neurons}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/5023: {on expression patterns}
- G01N 33/5058: {Neurological cells}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- C12N 2500/25: Insulin-transferrin; Insulin-transferrin-selenium
- C12N 2500/46: Amines, e.g. putrescine
- C12N 2501/01: Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C12N 2501/13: Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/392: Sexual steroids
- C12N 2501/41: Hedgehog proteins; Cyclopamine (inhibitor)
- C12N 2501/50: Cell markers; Cell surface determinants
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2501/604: Klf-4
- C12N 2501/70: Enzymes
- C12N 2501/71: Oxidoreductases (EC 1.)
- C12N 2503/02: Drug screening
- C12N 2506/1307: from adult fibroblasts
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2740/15032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12Q 2600/136: Screening for pharmacological compounds
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided.

## Claims

### Claim 1

A method of producing dopaminergic cells from a patient having a diagnosis of Parkinson's disease or Parkinson's-like disease, the method comprising:
a. obtaining fibroblasts from the patient;
b. dedifferentiating the fibroblasts; and
c. differentiating the stem cells towards a dopaminergic cell fate.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1 wherein the stem cells are differentiated towards a midbrain dopaminergic cell fate.

### Claim 4 (depends on 1)

The method of claim 1 wherein dedifferentiating the fibroblasts induces pluripotency.

### Claim 5 (depends on 1)

The method of claim 1 wherein the patient carries a genetic variation or mutation known to be associated with Parkinson's disease or Parkinson's-like disease.

### Claim 6 (depends on 5)

The method of claim 5 wherein the genetic variation of interest is a copy number variation of a gene of interest.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cell line has three copies of the gene of interest.

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 7)

The method of claim 7 wherein the gene of interest is PARK1 (SNCA or α-synuclein).

### Claim 11 (depends on 6)

The method of claim 6 wherein the gene of interest is PARKS (LRRK2).

### Claim 12 (depends on 11)

The method of claim 11 wherein the patient carries a homozygous mutation of LRRK2.

### Claim 13 (depends on 12)

The method of claim 12 wherein the mutation comprises a G2019S mutation.

### Claim 14 (depends on 1)

The method of claim 1 wherein the patient has Parkinson's disease.

### Claim 15

(canceled)

### Claim 16

A method of determining whether an agent is useful in the treatment of Parkinson's disease or Parkinson's-related disease, the method comprising:
a. contacting dopaminergic cells produced from induced pluripotent stem cells derived from a patient with Parkinson's disease or Parkinson's-like disease;
b. detecting a response in the cells; and
c. determining whether the agent is useful in the treatment based on the detected response.

### Claim 17 (depends on 16)

The method of claim 16 wherein the detected response is a change in cell viability, cellular chemistry, cellular function, mitochondrial function, cell aggregation, cell morphology, cellular protein aggregation, gene expression, cellular secretion, or cellular uptake.

### Claim 18 (depends on 16)

The method of claim 16 wherein the agent is selected from a small molecule, a drug, an antibody, a hybrid antibody, an antibody fragment, a siRNA, an antisense RNA, an aptamer, a protein, or a peptide.

### Claim 19 (depends on 16)

The method of claim 16 wherein the agent corrects an α-synuclein dysfunction.

### Claim 20 (depends on 19)

The method of claim 19 wherein the agent is selected from the group consisting of apomorphine, pyrogallol, 1,4-naphthoquinone, cisplatin, isoproterenol, pyrogallin, cianidanol, sulfasalazine, quinalizarin, benserazide, hexachlorophene, pyrvinium pamoate, dobutamine, methyl-dopa, curcumin, berberine chloride, daidzein, merbromin, norepinephrine, dopamine hydrochloride, carbidopa, ethylnorepinephrine hydrochloride, tannic acid, elaidyphosphocholine, hydroquinone, chlorophyllide Cu complex Na salt, methyldopa, isoproterenol hydrochloride, benserazide hydrochloride, dopamine, dobutamine hydrochloride, thyroid hormone, purpurin, sodium beta-nicotinamide adenine dinucleotide phosphate, lansoprazole, dyclonine hydrochloride, pramoxine hydrochloride, azobenzene, cefamandole sodium, cephaloridine, myricetin, 6,2′,3′-trihydroxyflavone, 5,7,3′,4′,5′-pentahydroxyflavone, 7,3′,4′,5′-tetrahydroxyflavone, (5,6,7,4′-tetrahydroxyflavone), baicalein, eriodictyol, 7,3′,4′-trihydroxyisoflavone, epigallocatechin gallate, quercetin, gossypetin (3,5,7,8,3′,4′-hexahydroxyflavone), 2′,3′-dihydroxyflavone, 3′,4′-dihydroxyflavone, 5,6-dihydroxy-7-methoxyflavone, baicalein-7-methyl ether, 1-dopa, DOPAC, homogentisic acid, 6-hydroxydopamine, epinephrine, 3,4-dihydroxycinnamic acid, 2,3-dihydroxynaphthalene, 3,4-dihydroxybenzoic acid, 3,4,5-trihydroxybenzoic acid, 1,2,3-trihydroxybenzoic acid, gallate (gallic acid), benzoquinone, catechol, rifampicin, rosmarinic acid, baicalin, tanshinones I and II, emodin, procyanidin B4, resveratrol, rutin, fisetin, luteolin, fustin, epicatechin gallate, catechin, alizarin, tannic acid, eriodyctol, carboplatin, purpurogallin-4-carboxylic acid, koparin, 2,3,4-trihydroxy-4′-ethexybenzophenone, baeomycesic acid, hamtoxylin, iriginol hexaaceatate, 4-acetoxyphenol, theaflavin monogallate, theaflavin digallate, stictic acid, purpurogallin, 2,5-dihydroxy-3,4-dimethoxy-4′-ethoxybenzophenone, promethazine hydrochloride, oxidopamine hydrochloride, pyrantel pamoate, elaidylphosphocholine, amphotericin B, gallic acid, fumarprotocetraric acid, theaflavin, haematoxylin pentaacetate, 4-methoxydalbergione, epigallocatechin-3-monogallate, rolitetracycline, 7,3′-dimethoxyflavone, liquiritigenin dimethyl ether, catechin pentaacetate, apigenin, 3,4-dedesmethyl-5-deshydroxy-3′-ethoxyscleroin, derivatives and analogs thereof.

### Claim 21 (depends on 16)

The method of claim 16 wherein the induced pluripotent stem cells are derived from human fibroblasts.

### Claim 22

(canceled)

### Claim 23 (depends on 16)

The method of claim 16 wherein the induced pluripotent stem cells are produced with a method comprising the use of three factors.

### Claim 24 (depends on 23)

The method of claim 23 wherein the three factors are OCT4, SOX2, and KLF4.

### Claim 25 (depends on 16)

The cell line of claim 16, wherein the induced pluripotent stem cells are further differentiated to adopt a midbrain dopaminergic cell fate.

### Claim 26 (depends on 25)

The cell line of claim 25 wherein the induced pluripotent stem cells are differentiated to adopt the cell fate in about 20 days.

### Claim 27 (depends on 16)

The method of claim 16 wherein the patient carries a genetic variation or mutation known to be associated with Parkinson's disease or Parkinson's-like disease.

### Claim 28 (depends on 27)

The method of claim 27 wherein the genetic variation of interest is a copy number variation of a gene of interest.

### Claim 29 (depends on 28)

The method of claim 28, wherein the cell line has three copies of the gene of interest.

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 29)

The method of claim 29 wherein the gene of interest is PARK1 (SNCA or α-synuclein).

### Claim 33 (depends on 31)

The method of claim 31 wherein the gene of interest is PARK8 (LRRK2).

### Claim 34 (depends on 33)

The method of claim 33 wherein the patient carries a homozygous mutation of LRRK2.

### Claim 35 (depends on 34)

The method of claim 34 wherein the mutation comprises a G2019S mutation.

### Claim 36 (depends on 16)

The method of claim 16 wherein the patient has Parkinson's disease.

### Claim 37

(canceled)

### Claim 38

An induced pluripotent cell line from a patient with Parkinson's disease or Parkinson's-like disease, produced by:
a. obtaining fibroblasts from a patient with Parkinson's disease or Parkinson's-like disease carrying a genetic mutation which causes the disease;
b. dedifferentiating the fibroblasts, whereby producing induced pluripotent stem cells; and
c. differentiating the stem cells towards a dopaminergic cell fate, whereby producing an induced pluripotent cell line from a patient with Parkinson's disease or Parkinson's-like disease.

### Claim 39

(canceled)

### Claim 40 (depends on 38)

The cell line of claim 38 wherein the pluripotent stem cells are differentiated towards a midbrain dopaminergic cell fate.

### Claim 41 (depends on 38)

The cell line of claim 38 wherein the patient carries a genetic variation or mutation known to be associated with Parkinson's disease or Parkinson's-like disease.

### Claim 42 (depends on 41)

The cell line of claim 41 wherein the genetic variation of interest is a copy number variation of a gene of interest.

### Claim 43 (depends on 42)

The cell line of claim 42, wherein the cell line has three copies of the gene of interest.

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46 (depends on 43)

The cell line of claim 43 wherein the gene of interest is PARK1 (SNCA or α-synuclein).

### Claim 47 (depends on 42)

The cell line of claim 42 wherein the gene of interest is PARK8 (LRRK2).

### Claim 48

The cell line of 47 wherein the patient carries a homozygous mutation of LRRK2.

### Claim 49 (depends on 48)

The cell line of claim 48 wherein the mutation comprises a G2019S mutation.

### Claim 50 (depends on 38)

The cell line of claim 38 wherein the patient has Parkinson's disease.

### Claim 51

(canceled)

### Claim 52 (depends on 38)

The cell line of claim 38 wherein the induced pluripotent cell line is produced without the use of a retrovirus or a lentivirus.

### Claim 53 (depends on 38)

The cell line of claim 38 wherein the induced pluripotent cell line is produced with a method comprising the use of three factors.

### Claim 54 (depends on 53)

The cell line of claim 53 wherein the three factors are OCT4, SOX2, and KLF4.

### Claim 55 (depends on 38)

The cell line of claim 38 wherein the induced pluripotent cell line is differentiated to adopt the cell fate in about 20 days.

### Claim 56

A human induced pluripotent cell line from a patient with Parkinson's disease wherein the cell line comprises a genetic variation related to Parkinson's disease.

### Claim 57 (depends on 56)

The cell line of claim 56 wherein the variation is triplication of the SNCA gene.

### Claim 58 (depends on 56)

The cell line of claim 56 wherein the variation is a homozygous mutation of the LRRK2 gene.

### Claim 59 (depends on 50)

The cell line of claim 50 wherein the induced pluripotent cell line is produced from fibroblasts of a patient with Parkinson's disease.

### Claim 60

(canceled)

### Claim 61

(canceled)

### Claim 62

(canceled)

### Claim 63 (depends on 56)

The cell line of claim 56, wherein the induced pluripotent cell line is further differentiated to adopt a midbrain dopaminergic cell fate.

### Claim 64 (depends on 63)

The cell line of claim 63 wherein the induced pluripotent cell line is differentiated to adopt the cell fate in about 20 days.

### Claim 65

A human induced pluripotent cell line wherein the cell line comprises a genetic variation in the SNCA gene or the LRRK2 gene.
